Gerosynth launches Mytulin EQ for equine recovery and immune support

Gerosynth Labs has launched Mytulin EQ, a new equine nutritional supplement marketed to support immune health, cellular vitality, performance recovery, musculoskeletal strength, gastrointestinal balance, and what the company describes as “mitochondrial rejuvenation.” The privately held Minnesota biotechnology company said the product is sold through its Mytosynth Nutraceuticals subsidiary and is derived from wild-harvested chaga mushrooms sourced from Alaska’s Arctic Circle. The launch was announced in a company press release carried by The Horse and PR Newswire in November 2025. (thehorse.com)

Why it matters: For equine veterinarians, this is another example of biotech-adjacent companies moving deeper into the horse supplement market with claims tied to recovery, resilience, and cellular health. That can create interest from trainers and pet parents, but it also raises familiar questions about evidence, labeling, and regulatory status. FDA’s Center for Veterinary Medicine says there is no separate “dietary supplement” category for animal products under DSHEA; products marketed for animals are generally regulated as either food or new animal drugs depending on intended use. In practice, that means veterinarians may be asked to weigh marketing claims against the available published evidence and the product’s actual regulatory footing. (fda.gov)

What to watch: Watch for any published equine data, broader veterinary uptake, and whether Gerosynth provides more detail on formulation, safety, or substantiation beyond its launch materials. (prnewswire.com)